Chidozie Ugwumba Sells 12,119 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 12,119 shares of the company’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $5.05, for a total transaction of $61,200.95. Following the completion of the transaction, the insider owned 617,824 shares of the company’s stock, valued at approximately $3,120,011.20. The trade was a 1.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The stock was sold at an average price of $4.80, for a total value of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The stock was sold at an average price of $5.13, for a total value of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The shares were sold at an average price of $5.10, for a total transaction of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total transaction of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The stock was sold at an average price of $4.89, for a total value of $127,653.45.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total transaction of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total value of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total transaction of $18,790.44.

Clene Trading Up 9.7%

Clene stock traded up $0.46 during mid-day trading on Wednesday, reaching $5.19. The company had a trading volume of 131,571 shares, compared to its average volume of 99,286. The stock’s 50-day simple moving average is $6.94 and its 200-day simple moving average is $6.50. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, research analysts anticipate that Clene Inc. will post -5.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Clene

Hedge funds and other institutional investors have recently modified their holdings of the stock. Lunt Capital Management Inc. raised its holdings in shares of Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after purchasing an additional 21,217 shares during the period. Scoggin Management LP grew its position in shares of Clene by 75.1% during the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares during the last quarter. Jane Street Group LLC acquired a new stake in Clene during the second quarter worth about $47,000. Finally, Jones Financial Companies Lllp acquired a new stake in Clene during the third quarter worth about $29,000. Institutional investors own 23.28% of the company’s stock.

Analyst Upgrades and Downgrades

CLNN has been the subject of several research analyst reports. Benchmark reaffirmed a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. UBS Group reiterated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Finally, D. Boral Capital restated a “buy” rating and set a $23.00 price target on shares of Clene in a research note on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Clene currently has a consensus rating of “Moderate Buy” and an average price target of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).